Looking to unseat Sanofi and Shire drugs, Atlas gene therapy startup Avrobio files for $86M IPO – FierceBiotech
FierceBiotech |
Looking to unseat Sanofi and Shire drugs, Atlas gene therapy startup Avrobio files for $86M IPO
FierceBiotech The offering would give the Atlas Venture-backed startup the means to run clinical trials of gene therapies designed to supplant enzyme replacement therapies from Sanofi, Shire and Pfizer. Cambridge, Massachusetts-based Avrobio’s approach entails … |
www.oncnursingnews.com/ |
Monitoring Adverse Effects of Immunotherapy
www.oncnursingnews.com/ Cancer immunotherapies are a promising development, but taking care of patients who are using these drugs can be a challenge for oncology nurses. After all, it isn’t exactly easy to monitor patients for adverse effects (AEs) that could arise in any of … |